Analysis reports / SIC major group
Chemicals And Allied Products financial report
SIC major group. Companies: 107. Companies with financial data: 107. Companies with revenue: 107. As of: 2026-05-26.
Mechanical ranking by stated metric from SEC/FRED data; not a recommendation, endorsement, or quality/investment judgment.
Chart
Distribution Summary
| Metric | Count | Median | Minimum | Maximum | Min-Max range |
|---|
| Net margin | 104 | 8.89% | -145.16% | 72.56% | 217.72% |
| Operating margin | 87 | 13.05% | -141.35% | 58.20% | 199.55% |
| Revenue growth | 106 | 2.34% | -89.41% | 23258.15% | 23347.56% |
Highest reported net margin
| Rank | Company | Net margin | FY | Extra |
|---|
| 1 | TGTX - TG THERAPEUTICS, INC. | 72.56% | 2025 | |
| 2 | INVA - Innoviva, Inc. | 65.92% | 2025 | |
| 3 | PTGX - Protagonist Therapeutics, Inc | 63.34% | 2025 | |
| 4 | KRYS - Krystal Biotech, Inc. | 52.64% | 2025 | |
| 5 | LGND - LIGAND PHARMACEUTICALS INC | 46.42% | 2025 | |
| 6 | UTHR - UNITED THERAPEUTICS Corp | 41.94% | 2025 | |
| 7 | PTCT - PTC THERAPEUTICS, INC. | 39.44% | 2025 | |
| 8 | ACAD - ACADIA PHARMACEUTICALS INC | 36.49% | 2025 | |
| 9 | CPRX - CATALYST PHARMACEUTICALS, INC. | 36.39% | 2025 | |
| 10 | EXEL - EXELIXIS, INC. | 33.73% | 2026 | |
Lowest reported net margin
| Rank | Company | Net margin | FY | Extra |
|---|
| 1 | MRNA - Moderna, Inc. | -145.16% | 2025 | |
| 2 | RCUS - Arcus Biosciences, Inc. | -142.91% | 2025 | |
| 3 | NEOG - NEOGEN CORP | -122.06% | 2025 | |
| 4 | XNCR - Xencor Inc | -73.20% | 2025 | |
| 5 | FMC - FMC CORP | -64.57% | 2025 | |
| 6 | QDEL - QuidelOrtho Corp | -41.45% | 2025 | |
| 7 | SDGR - Schrodinger, Inc. | -40.36% | 2025 | |
| 8 | PRGO - PERRIGO Co plc | -33.51% | 2025 | |
| 9 | SRPT - Sarepta Therapeutics, Inc. | -32.45% | 2025 | |
| 10 | VTRS - Viatris Inc | -24.58% | 2025 | |
Highest reported operating margin
| Rank | Company | Operating margin | FY | Extra |
|---|
| 1 | PTGX - Protagonist Therapeutics, Inc | 58.20% | 2025 | |
| 2 | VIR - Vir Biotechnology, Inc. | 51.56% | 2025 | |
| 3 | PTCT - PTC THERAPEUTICS, INC. | 50.09% | 2025 | |
| 4 | UTHR - UNITED THERAPEUTICS Corp | 46.89% | 2025 | |
| 5 | CPRX - CATALYST PHARMACEUTICALS, INC. | 43.77% | 2025 | |
| 6 | KRYS - Krystal Biotech, Inc. | 41.45% | 2025 | |
| 7 | INVA - Innoviva, Inc. | 39.81% | 2025 | |
| 8 | EXEL - EXELIXIS, INC. | 37.59% | 2026 | |
| 9 | ADMA - ADMA BIOLOGICS, INC. | 37.53% | 2025 | |
| 10 | NGVT - Ingevity Corp | 35.86% | 2025 | |
Lowest reported operating margin
| Rank | Company | Operating margin | FY | Extra |
|---|
| 1 | XNCR - Xencor Inc | -141.35% | 2025 | |
| 2 | RCUS - Arcus Biosciences, Inc. | -127.91% | 2025 | |
| 3 | MRNA - Moderna, Inc. | -121.91% | 2025 | |
| 4 | NEOG - NEOGEN CORP | -118.59% | 2025 | |
| 5 | SDGR - Schrodinger, Inc. | -65.23% | 2025 | |
| 6 | FMC - FMC CORP | -46.96% | 2025 | |
| 7 | QDEL - QuidelOrtho Corp | -33.67% | 2025 | |
| 8 | SRPT - Sarepta Therapeutics, Inc. | -31.83% | 2025 | |
| 9 | PRGO - PERRIGO Co plc | -26.39% | 2025 | |
| 10 | VTRS - Viatris Inc | -18.62% | 2025 | |
Largest reported revenue growth
| Rank | Company | Revenue growth | FY | Extra |
|---|
| 1 | ARWR - ARROWHEAD PHARMACEUTICALS, INC. | 23258.15% | 2025 | |
| 2 | CYTK - CYTOKINETICS INC | 376.56% | 2025 | |
| 3 | PTCT - PTC THERAPEUTICS, INC. | 114.51% | 2025 | |
| 4 | TGTX - TG THERAPEUTICS, INC. | 87.32% | 2025 | |
| 5 | LGND - LIGAND PHARMACEUTICALS INC | 60.40% | 2025 | |
| 6 | LLY - ELI LILLY & Co | 44.70% | 2025 | |
| 7 | ANIP - ANI PHARMACEUTICALS INC | 43.78% | 2025 | |
| 8 | HALO - HALOZYME THERAPEUTICS, INC. | 37.55% | 2025 | |
| 9 | KRYS - Krystal Biotech, Inc. | 33.94% | 2025 | |
| 10 | PAHC - PHIBRO ANIMAL HEALTH CORP | 27.37% | 2025 | |
Informational only - not investment advice.